Combination therapy to boost CAR-T for B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell lymphoma (like diffuse large B-cell lymphoma or high-grade B-cell lymphoma) that shows the CD19 or CD22 protein on the cancer cells.
- Your lymphoma did not fully respond to initial chemotherapy, or it came back within 6 months after finishing treatment, or you have certain high-risk features like 'double-hit' genetics.
- You have not had CAR-T cell therapy before.
- You are 18 to 85 years old, able to care for yourself (ECOG score 0–2), and have adequate blood counts and heart, liver, kidney, and lung function.
- You do not have an active serious infection (like uncontrolled HIV or hepatitis B), recent heart problems, or another cancer that has been active within the last 3 years.
- You are willing to follow the study schedule and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests a new two-step treatment: first a small dose of radiation (131I-Apamistamab) followed by specially designed immune cells (CAR-T cells) to fight your lymphoma. It is for people with DLBCL that has relapsed or not responded to standard therapy.
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
Hear when a new Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.